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Human interleukin-7 (hIL-7) is a cytokine secreted by the stromal cells of the red marrow. It is important for proliferation during
certain stages of B-cell maturation and for T and NK cell survival, development, and homeostasis. It is a critical growth factor for
enhancement and recovery of the immune T-cell. Because of its strong immunomodulatory eﬀects, hIL-7 may become a valuable
supplementary agent for immunotherapeutical treatments in patients with HIV infection or immunodeﬁciency. Human IL-7 has
previously been produced in various protein expression systems. In this paper, we present an alternative expression system, in
Spodoptera frugiperda cells, for the production of hIL-7 using nonlytic vector systems. This system allows generation of correctly
translated and accurately processed heterologous proteins as soluble recombinant proteins. Here we report plasmid construction,
transfection, and consequent expression of hIL-7 using this nonlytic insect cell expression system. The levels of secreted hIL-7 in a
small scale experiment reached a level of 1.7μg·1
−1 under serum-free cell culture conditions.
Copyright © 2009 Maryam Mirzaei et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Recombinant proteins produced in insect cell systems are
useful for fundamental research in cell and molecular biol-
ogy. In addition, they are important for commercial produc-
tion of reagents, therapeutics, and vaccines for agriculture
and human health applications [1]. To produce recombinant
protein in insect cells, baculovirus expression vector system
(BEVS) is a suitable and widely used eukaryotic system [2–5]
for high-level expression of heterogonous proteins. However,
for production and puriﬁcation of proteins, this system
has a number of disadvantages including the transience of
virus-based expression and the considerable eﬀort required
for scale-up and maintenance of virus stocks. In addition,
viral proteases and cell lysates can cause degradation of the
d e s i r e dp r o t e i n sa n di ti sd i ﬃcult to separate recombinant
protein from recombinant virus particles [2, 6]. In order
to resolve these problems, an alternative approach using a
nonlytic, virus-free expression system has been adopted [7,
8] that uses early baculovirus promoters in either transiently
or stably transformed cells from Drosophila melanogaster,
mosquito, as well as Spodoptera cells [8–11]. In contrast
to baculovirus infected cells, stable insect cells are able to
continuously produce soluble recombinant proteins, which
facilitate protein puriﬁcation [7] and the proteins are also
properly modiﬁed. However, the rate of protein expression
in stably transformed cells is often lower than that of a
conventional baculoviral system.
In this study we used a nonlytic system to produce
human IL-7 (hIL-7). Human IL-7 is a single-chain 25kDa
protein ﬁrst identiﬁed in bone marrow cultures through its
pre-B cell growth factor properties; it was later described as a
potent T-lymphocyte growth factor [12–14]. It is produced
locally by intestinal epithelial and epithelial goblet cells
and may serve as a regulatory factor for intestinal mucosal
lymphocytes. IL-7 develops and activates lymphocytes; it
also stimulates lymphopoiesis in lymphopenic mice [15, 16].
These ﬁndings suggest a possible clinical application of IL-72 Journal of Biomedicine and Biotechnology
for accelerating lymphoid reconstitution in lymphopenic
patients. A number of preclinical studies have demonstrated
possible functioning of IL-7 in antitumor clinical applica-
tions and gene therapy for metastatic diseases. IL-7 can also
promote engraftment of stem cells in mice receiving bone
marrow transplants, leading to a possible use of hIL-7 in
patients receiving bone marrow orperipheral blood stemcell
transplants [12].
To examine the expression and production of hIL-7
in a nonlytic, baculovirus-free expression system, we used
a stably transfected insect cell system cotransfected with
an expression vector containing a silk moth-Bombyx mori
promoter and a resistance plasmid carrying a selectable
marker puromycin gene [7, 17, 18]. For comparison pur-
poses, we used another plasmid containing OpIE2 promoter
for high-level, constitutive expression of the gene of interest
containing a Zeocin resistancegeneforselection of stablecell
lines [19, 20]. We also examined production of hIL-7 in Sf9
insect cells using BEVS.
2.MaterialsandMethods
2.1. Cells and Media. Spodoptera frugiperda, Sf9 cells (Invit-
rogen, Carlsbad, Calif, USA) were cultured in SF-900 II
medium (Invitrogen, Carlsbad, Calif, USA) and incubated in
a shaker incubator at a temperature of 27◦C and 115rpm.
The cells were maintained by passaging 1 to 2 times weekly
at an initial cell density of 4-5 × 105 cells·mL−1. During this
process, the total and viable cell densities and the cell size
were measured using the automated Trypan blue exclusion
method (Cedex, Innovatis, Bielfeld, Germany).
2.2. Plasmid. Nonlytic Triple Express Insect Expression Sys-
tem: pIE1/153A (V4) (Cytostore, Calgary, Alberta, Canada)
and plasmid pBmA·pac (Cytostore, Calgary, Alberta,
Canada) carrying a selectable marker puromycin gene were
used. For comparison the basic vector pIZ/V5-His (Invitro-
gen, Carlsbad, Calif, USA) was also used.
2.3. Construction of Expression Vector. The hIL-7 gene was
ampliﬁed by PCR from pORF9-hIL07 transfer vector
(InvivoGen, Hornby, Ontario, Canada) using oligonu-
cleotide primers: Forward: GCCTACCTGGGATCCGGTCA-
AC and Reverse: TCATCAATGTATGCGGCCGCCTTAT-
CATGTCGAG and Vent polymerase (New England BioLabs,
Ipswich, Mass, USA). The PCR product was subcloned into
the BamHII and NotI site of pIE1/153A (V4) vector. The
recombinant plasmids containing hIL-7 cassette in frame
were conﬁrmed by restriction endonuclease digestion and
DNA sequencing.
2.4. Cell Culture and Transient Transfection. Sf9 cells were
seeded into six-well plates at a density of 5 × 105 cells·mL−1
(2mL per well). Cells were cotransfected with the plasmids
pIE1/153A.hIL-7 and pBmA·pac or pIZ/V5-His.hIL-7 using
Cellfectin (Invitrogen, Carlsbad, Calif, USA). The mixture
was incubated for 45 minutes then added to the cells and
incubated for 5 hours at 27◦C. The medium was then
replaced with fresh medium (SF900 II) and the cultures
further incubated at 27◦C. One week later, transfected cells
were transferred to a medium containing puromycin (Gibco
BRL) at a ﬁnal concentration of 5μg·mL−1 in the case of
pIE1/153A.hIL-7 (or 500μg·mL−1 Zeocin in the case of
pIZ/V5-His.hIL-7 transfection) and incubated for 3 weeks.
To allow selection of resistant cells, transfected cells were
propagated for a further 2 weeks in Sf900II supplemented
with appropriate antibiotics.
After this initial selection, cell cultures were maintained
in media lacking any antibiotics. To establish clonal cell
lines, the cells were harvested by gentle scraping, aliquots
were transferred to 24-well plates and the plates were
incubated for seven days at 27◦C. The media were changed
every 2 days with fresh media supplemented with an
appropriate antibiotic. Individual colonies were selected and
transferred to 96-well plates using a micropipette. After 5–
7 days, cells were ampliﬁed in Sf900II until suﬃcient cell
concentrations were present for analysis. Polyclonal cell lines
were maintained at 27◦C in Sf900II. Using a micropipette,
ten to twelve well-isolated antibiotic-resistant colonies from
a 96-well plate were selected, and the hIL-7 expression
levels from the supernatant of each stable polyclone were
examined by Western blot analysis. Cells were maintained
in antibiotic-free medium for 20 passages and the stability
of the transfected cells was monitored using western blots
analysis.
2.5. Expression of Recombinant hIL-7 in Stably Transfected
Insect Cells. For the expression of recombinant proteins, a
pool of stably transfected Sf9 cloned cells was grown in
serum-freemedium(Sf900-II)inshakerﬂasks.Thecellswere
seeded at a density of 5 × 105 cells·mL−1 and their growth
was monitored by taking samples. The total and viable
cell densities as well as cell size were measured (using the
automated Trypan blue exclusion method, Cedex, Innovatis,
Bielfeld, Germany). The experiment was performed in
triplicate and samples were taken at regular intervals. The
cell lines were frozen using freezing media (10% FBS, 10%
DMSO, and 80% Sf900 II) and stored in liquid nitrogen for
further analysis.
2.6. Production of hIL-7 in Insect Cells Using BEVS. Plasmid
construction, bacmid preparation, insect cell transfection,
and baculovirus stock preparation have been described
elsewhere [21]. For comparison assays, recombinant bac-
ulovirus containing human interleukin-7 (rbac/hIL-7) was
used at a multiplicity of infection (MOI) between 5 to
0.5 to infect Sf9 cells. The cells were cultured in shaker
ﬂasks and were incubated at 27◦C with agitation at 115rpm.
Samples were taken at regular intervals of 24, 48, 72, and
96 hours post-infection (hpi). Total and viable cell densities
and cell size were measured using the automated Trypan
blueexclusionmethod(Cedex,Innovatis,Bielfeld,Germany)
during the infection process. Cell cultures were separated
into supernatant and pellets by centrifugation.Journal of Biomedicine and Biotechnology 3
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Figure 1: Construction of the pIE1/153A (V4) expression plasmid carrying the hIL-7 gene. The hIL-7 gene from pORF9-hIL07 vector was
inserted in pIE1/153A(V4) expression plasmid, pIE1/153A(V4)/hIL-7 and pBmA-pac were cotransfected into Sf9 cells. Clones producing
hIL-7 were selected using puromycin and analyzed by western blot and SDS page.
2.7. Analytical Sssays. The amount of hIL-7 in supernatants
was measured by sandwich ELISA using rabbit antihuman
IL-7 antibody (RDI, Mass, USA) as the capture antibody and
a biotinylated monoclonal antihuman IL-7 (R&D systems,
Ontario, Canada) as the detection antibody. Streptavidin-
horseradish peroxidase (R&D systems, Ontario, Canada)
was used for conversion of a substrate mixture containing
stabilized hydrogen peroxide and stabilized tetramethyl-
benzidine (R&D systems, Ontario, Canada). The reactions
were terminated by adding H2SO4, and the absorbance
was measured at 450nm using 570nm as the reference
wavelength. Commercially available puriﬁed human IL-
7(R&D systems, Ontario, Canada) was used as a standard.
2.8. Western Blot Analysis. The expression of human inter-
leukin-7 was determined using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). 15μlo f
samples were loaded to the gel and detected using a pol-
yclonal rabbit antihuman IL-7 (RDI, Flanders, NJ, USA) as
the primary antibody. The blots were developed using the
chemiluminescence kit (Boehringer Mannheim, Mannheim,
Germany) and visualized with the Kodak manager system.
2.9. hIL-7 Biological Sssay. Recombinant hIL-7 proteins
p r o d u c e di n2d i ﬀerent clones were tested for their
bioactivity using induction of in vitro proliferation of an
IL-7-dependent murine immature B lymphocyte cell line
2E8 (ATCC: TIB 239) as a measure of activity. 2E8 cells were
maintained at 37◦Ci na5 %C O 2 atmosphere in Isocove’s
modiﬁed Dulbecco’s medium (ATCC, Manassas, Va, USA)
supplemented with 0.05mM 2-mercaptoethanol, 2mM
glutamine, 50IU/mL penicillin, 50mg/mL streptomycin,
5ng/mL IL-7, and 5% fetal bovine serum (Sigma-
Aldrich, Oakville, Ontario, Canada). IL-7 was found to
remain biologically active in the presence of 0.05mM
2-mercaptoethanol. Cell proliferation was detected by4 Journal of Biomedicine and Biotechnology
14
17
28
38
49
62
98
188
(
K
D
a
)
12 3456 7 89 1 0 1 1
Figure 2: Screening of puromycin resistant clones in Sf9 cells co-
transfectedwithpIE1/153A(V4)expressionplasmidcarryinghIL-7
gene and pBmA-pac carrying puromycin resistance gene. Cells were
placed in medium containing puromycin at a ﬁnal concentration
of 5μgmL−1 for 3 weeks. Lane 1: protein marker. Lanes 2–11:
polyclones Sf9hIL-7G, Sf9hIL-7E, Sf9hIL-7F, Sf9hIL-7A1, Sf9hIL-
7B4, Sf9hIL-7D5, Sf9hIL-7H, Sf9hIL-7C1-2, Sf9hIL-7C1-3, and
Sf9hIL-B4-1, respectively.
tetrazolium compound [3-(4, 5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling
reagent (phenazine methosulfate: PMS) (Promega, Madison,
Wis). For proliferation assays, 2E8 cells were washed three
times and seeded at a density of 1 × 105 cells/well in 96-well
plates in 50μl of medium containing no IL-7. A 50μla l i q u o t
of crude protein was added to each well to give a range of
concentrations from 0.01 to 100ng/mL in a ﬁnal volume
of 100μl. After 72-hours incubation, a 20-μla l i q u o to f
MTS-PMS (according to the manufacturer’s protocol) was
added to each well and incubated at 37◦Cf o r4h o u r s .
MTS is bioreduced by cells into a formazan product that
is soluble in tissue culture medium. The absorbance of the
formazan at 490nm can be measured directly from 96-well
assay plates without additional processing. Commercially
available rhIL-7 preparations were used to establish the 2E8
Bioassay. Medium alone served as a negative control, and
each sample was assayed in triplicate.
3. Results andDiscussion
The hIL-7 gene was obtained by PCR reaction and diges-
tion with NotI and BamHI enzymes from pORF9-hIL07
transfer vector, which were used to facilitate the insertion
of the gene into the cut pIE1/153A (V4) or pIZ/V5-His
expression vector plasmids. Cloned plasmids were then
transferred to competent E.coli cells, puriﬁed according to
the manufacturer’s protocol, and used for transfection of Sf9
cells. Figure 1 illustrates the construction of pIE1/153A (V4)
expression plasmid carrying hIL-7 gene (pIE1/153A.hIL-7)
and the transfection procedure of the constructed plasmid
into the Sf9 insect cells. For transfection, pIE1/153A.hIL-
7 plasmid was cotransfected with plasmid pBmA.pac con-
taining puromycin resistance gene into the insect cells. The
expression characteristics of the recombinant hIL-7 protein
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Figure 3: Growth curves of the stably transfected Sf9 producing
hIL-7 and nontransfected Sf9 insect cells. (a) Viable cell density,
total cell density, and viability of stably transfected Sf9 with
pIE1/153A (V4)/hIL-7 plasmid. Cells were seeded at a density of
5×105 cells·mL−1 and maintained at 1×107 cells·mL−1. (b) Viable
cell density, total cell density, and viability of nontransfected Sf9
insect cells. Cells were seeded at a density of 5 × 105 cells·mL−1
(n = 3).
were analyzed by western blotting using hIL-7 speciﬁc
antibody, as presented in Figure 2, which shows preliminary
results for screening of positive clones. In Sf9 insect cells,
production and processing of hIL-7 proceeded normally,
resulting in a protein with molecular weight similar to
that produced in mammalian cells. The most productive
polyclone (Sf9hIL-7A1) was selected for further study.
Stable expression was veriﬁed by maintaining the Sf9hIL-
7A1polycloneinpuromycin-freemediumaftertheselection.
The expression of hIL-7 remained stable during more than
15 cell passages and cells could be maintained further in
selection-free media without any decrease in their produc-
tion. The cell lines were successfully frozen and retrieved
from liquid nitrogen using the same procedures used for Sf9
cells. Figure 3 shows a growth curve over an 11-day period
in Sf900 II for Sf9hIL-7A1 compared to nontransfected
Sf9 insect cells. The cells appeared healthy and displayed
an average doubling time of 24 hours. As shown in
Figure 3(a), cell densities increased exponentially over theJournal of Biomedicine and Biotechnology 5
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Figure 4:GrowthcurveofthestablytransfectedSf9producinghIL-
7 and nontransfected Sf9 insect cells. (a) Viable cell density, total
cell density, and viability of stably transfected Sf9 with pIZ/V5-hIL-
7 plasmid. Cells were seeded at a density of 5 × 105 cells·mL−1 and
maintained at 1 × 107 cells·mL−1. (b) Viable cell density, total cell
density, and viability of nontransfected Sf9 insect cells. Cells were
seeded at a density of 5 ×105 cells·mL−1 (n = 3).
ﬁrst six days and then appeared to plateau between days
six to eight, reaching maximum densities of approximately
8 × 106 cells·mL−1. Culture viabilities remained high (above
95%) until day seven but then dropped to below 70% by
day eleven. Culture viabilities ranged from 95% to 99.5%,
withmostdeterminations above 97% during the exponential
stage, which was similar to nontransfected Sf9 insect cells
(Figure 3(b)).
For comparison, we cloned the nucleotide sequences
corresponding to the hIL-7 protein into the pIZ/V5-His
expressionvectorandconstructedthepIZ/V5-His.hIL-7vec-
tor. This plasmid is an immediate early expression plasmid
where the coding sequence for hIL-7 is positioned under the
transcription control of the OpIE2 promoter. The promoter
is derived from a second immediate early regulatory gene
of the baculovirus Orgyia pseudotsugata multicapsid nuclear
polyhedrosis virus (OpMNPV) which was identiﬁed in 1992
[20, 22]. Insect cells were then transfected with pIZ/V5-
His.hIL-7 and stable transfectants were selected with zeocin,
a glycopeptide antibiotic of the bleomycin family, which
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Figure 5: Production proﬁle of hIL-7 in stably transfected Sf9 with
two diﬀerent expressions, cells were grown in serum-free medium
(Sf900-II) in shaker ﬂasks. The amount of hIL-7 in supernatants
was measured by sandwich ELISA using rabbit antihuman IL-7
antibodyasthecaptureantibodyandamonoclonalantihumanIL-7
as the detection antibody. Streptavidin-horseradish peroxidase was
used for conversion of a substrate mixture containing stabilized
hydrogen peroxide, and stabilized tetramethylbenzidine commer-
cially available as puriﬁed human IL-7 was used as a standard
(n = 3).
is active in vivo against most bacteria (including E. coli),
eukaryotic microorganisms (i.e., yeasts), plant cells, and
animal cells [19]. The most productive polyclonals, grown
with Sf900II medium in shake ﬂasks at 27◦C and 120rpm
from an initial concentration of 5 × 105 cell·mL−1,r e a c h e d
a maximum cell density of approximately 8 × 106 cell/mL
on the fourth day of culture with a cell viability of 93%
(Figure 4(a)). This demonstrated that stable transfection of
pIZ/V5-His.hIL-7 into Sf9 cells did not cause signiﬁcant
changes in the growth of the transfected Sf9-hIL-7 cells
nor in the cell viability, when compared to growth curves
of wild-type Sf9 cells obtained under the same conditions
(Figure 4(b)).
Secreted protein was measured in cell culture super-
natants collected every 24 hours for 1–11 days (Figure 5)a n d
its concentration was determined by ELISA. The quantity of
hIL-7 in supernatants attained a maximum accumulation of
1.7μg·l−1 of cell culture supernatant. As shown in Figure 5,
production of hIL-7 was generally still increasing in the
supernatant on day 11. In case of the cells transfected with
pIZ/V5-His.hIL-7, production of the recombinant hIL-7
increasedtoavalueof1μg·l−1 ontheeleventhdayofculture.
Recombinant hIL-7 produced in both systems was
assayed for biological activity by measuring the stimulation
of IL-7-dependent 2E8 cell proliferation in vitro. Maximal
stimulationofproliferationoccurredinthepresenceofhIL-7
and no diﬀerence was seen in the ability of recombinant hIL-
7 to induce the proliferation of cell populations compared
with that of the commercially available puriﬁed hIL-7. As
shown in Figure 6, incubation with hIL-7 concentrations
above 1ng/mL resulted in an increase in the A490nm of
2E8 cell cultures, with no activity seen at lower hIL-7
concentrations. The bioactivity of the rhIL-7 produced by
both recombinant systems is very similar.
We compared productivity of hIL-7 in Sf9 cells using
BEVS. To infect cells, diﬀerent multiplicity of infection was6 Journal of Biomedicine and Biotechnology
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Figure 6: Biological activity assay of recombinant human IL-
7 produced in insect cells. IL-7-dependent murine immature B
lymphocyte cell line 2E8 was used for proliferation assay. After
72 hours incubation at 37◦Ci na5 %C O 2 atmosphere, cell
proliferation was detected by tetrazolium compound MTS and an
electron coupling reagent PMS. The absorbance of the formazan
was measured at 490nm. Commercially available rhIL-7 was used
to establish the 2E8 bioassay. Medium alone served as a negative
control, and each sample was assayed in triplicate (n = 3).
used. As shown in Figure 7, the ﬁnal viable cell density of
the uninfected cells (control) was much higher than those
of cells infected by recombinant virus. The number of viable
cells increased to more than 10 × 106 cells/mL by 96 hours
in the control and decreased to less than 1 × 106 cells/mL
in cells infected with the virus. In addition, the viability of
infected cells decreased after 48 hpi, to less than 60%. There
was no signiﬁcant diﬀerence in viability between control
cells over a period of 96 hpi. The Western blot data shown
in Figure 8 indicate that hIL-7 is produced and processed
normally in the BEVS system to generate a protein with a
similar molecular weight to that produced in mammalian
cells. The protein was found in both the supernatant and the
cell lysates, however, the intracellular protein was found to
have multiple molecular weights. These diﬀerent molecular
forms are likely a result of incomplete glycosylation which
may occur in this system.
In general BEVS produced higher amounts of recom-
binant hIL-7, as ELISA revealed that the expression level
was almost 10 times greater in BEVS than in the stably
transfected insect cells [21]. For production of hIL-7 in
BEVS, a strong polyhedrin (PH) promoter for high-level
protein expression was used. In this case, the baculovirus can
synthesize recombinant protein in infected cells, polyhedrin
eventually constitutes up to 50% of the total protein in the
cell. This promoter has been used to construct expression
vectorstoallowhighlevelofexpressionofthegeneofinterest
under the inﬂuence of this promoter. In contrast, in the
case of stably transfected insect cells, the silk moth-Bombyx
mori promoter was used. This promoter is a region of the
genome of Bombyx mori nuclear polyhedrosis virus (Bm-
NPV) containing the homologous region 3 (HR3), which
acts as an enhancer for the promoter of a nonviral gene,
the cytoplasmic actin gene of the silkmoth. On the other
hand, stable cultures, initiated with a lower cell density at
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Figure7:V iablecelldensity ,totalcelldensityandviabilityoftheSf9
insect cells infected with diﬀerent MOI of rbacmid/hIL-7. Diﬀerent
multiplicity of infection (MOI) between 5 to 0.5 was used. Sf9 cells
were cultured in shaker ﬂasks and incubated at 27◦Cw i t ha g i t a t i o n
at 115rpm. Samples were taken at regular intervals (24, 48, 72, and
96) hpi. (a), (b), (c) Infected cells with MOI:5, 1 and 0.5 of the virus
stock, respectively. (d) Control (Noninfected insect cells) (n = 3).Journal of Biomedicine and Biotechnology 7
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Figure 8: Western blot analysis of the intra- and extracellular of rhIL-7 produced in Sf9 insect cells. (a) Intracellular protein in Sf9: (lanes 1–
3: 24hpi, using MOI 5, 1 and 0.5 of the virus stock, respectively, lanes 4–6 48hpi. Lanes 7–9: 72hpi and lanes 10–12 96hpi). (b) Extracellular
protein in Sf9: (lanes: 2–4 24hpi using MOI 5, 1 and 0.5 virus stock, respectively, lanes: 5–7 48hpi, lanes: 8–10 72hpi, lanes: 11–13 96hpi).
5×105 cell/mL, grew until they reached a maximal viable cell
density of 13.3 × 106 cell/mL; whereas, the cells infected at
2 × 106 cell/mL cell density in case of BEVS reached a viable
cell density of only 3.5 × 106 cell/mL. Viability of BEVS cells
dropped to 10–20% at 96 hours post infection while in stably
transfected insect cells, viability was maintained at 80–99%
for 240 hours incubation.
Generally, BEVS has been used for the high-level expres-
sion of eukaryotic genes in insect cells, as it is a rapid and
convenient system for production of many diﬀerent foreign
proteins. The simplicity and rapidity of the vector system are
two of its most important characters [2, 23], which make
BEVS a powerful system for high-level, recombinant protein
expression in insect cells. On the other hand, stable insect
expression systems have advantages of both baculovirus and
mammalian expression systems. They are also simple to
use, with uncomplicated techniques for transfection and
selection similar to those used with mammalian expression
systems. Stable insect systems often reach higher levels of
expression than do mammalian systems and are especially
useful for production of secreted proteins [7].
In this study, we successfully established stably trans-
fected insect cell lines for the production of recombinant
hIL-7. We have demonstrated that these stably transfected
cells can be used as an alternative to BEVS for large scale
production of recombinant hIL-7. The levels of secreted
human interleukin-7 in our small scale study reached
1.7μg·l−1 under serum-free cell culture conditions (in the
case of the pIZ/V5-His.hIL-7 plasmid we obtained 1μg·l−1).
In particular, the stable system using the expression vector
pIE1/153A (V4) constitutes an advance for the expression
of hIL-7 and possibly other glycoproteins in insect cells.
This expression plasmid contains a silk moth-Bombyx mori
promoter for high-level expression of the recombinant
protein and a resistance plasmid which carries a selectable
marker puromycin gene for selection of the transfected cells
[7]. It was ﬁrst constructed by Farrel et al. [7, 18]f o r
continuoushigh-levelexpressionofsecretedglycoproteinsby
transformed lepidopteran insect cells and was developed as
an alternative to baculovirus and mammalian cell expression
systems. The expression cassette has the promoter of the
silkmoth cytoplasmic actin gene, to drive expression of
foreign gene sequences and also contains a transactivator
gene and enhancer region of BmNPV, to stimulate gene
expression. Since it is a nonlytic system, the glycoproteins
obtained are probably more suitable for structural and
functional studies.
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